Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
Benjamin Levy(Johns Hopkins University), Jonathan W. Riess(University of California Davis Medical Center), Ronald Scheff(Cornell University), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), J. Madelaine(Université de Caen Normandie), Jaafar Bennouna(Hôpital Foch), Michael Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hye Ryun Kim(Yonsei University), Mustafa Erman(Hacettepe University Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Firas Badin, Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Olivier Molinier(Centre Hospitalier du Mans), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Fabrice Barlési(Hôpital Nord), Enriqueta Felip(Institut Català d'Ornitologia), Sang-We Kim(Asan Medical Center), Clarisse Audigier-Valette(Hôpital d'Instruction des Armées Sainte-Anne), Tarek Mekhail(AdventHealth Orlando), Behbood Sadrolhefazi(Boehringer Ingelheim (Canada))
Cited by 10
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k